MINNEAPOLIS, Sept. 26 -- Medtronic, Inc. (NYSE: MDT) announced it has
received CE (Conformite Europeenne) Mark for its Medtronic CoreValve(R)
Evolut(TM) 23mm valve, its latest self-expanding transcatheter aortic
valve implantation (TAVI) system. The new valve incorporates technology
that optimizes fit, thereby promoting sealing between the prosthetic
valve and the native valve (TruFit Technology). The Medtronic CoreValve
System is currently limited to investigational use in the United States. They just started clinical trial activities in the US.
Medtronic had acquired CoreValve for about $700 Million. CoreValve set the precedent that OUS clinical study is really valuable. CoreValve's technology was in the aortic valve market which is approx a $4 B market worldwide.
With the introduction of the CoreValve Evolut valve, Medtronic can now treat the broadest range of TAVI patient valve sizes (annulus diameters from 18mm to 29mm).
The Medtronic CoreValve System received CE (Conformite Europeenne) Mark in 2007. Medtronic now offers TAVI in four valve sizes (23mm, 26mm, 29mm and 31mm), each deliverable via transfemoral, subclavian and direct aortic access through a low-profile, 18Fr delivery catheter.
There are a few new start ups in the cardiac valves space, Micardia, spunoff a percutaneous approach and ORbimed invested in the company. Its wierd, Edwards is heavy in the space, market size is $4 B.
Medtronic's Ex CEO, Mr Bill Hawkins mentioned at the Cleveland Clinic Innovation Summit focused on Obesity. He mentioned that Medtronic's will be focusing on obesity and related problems. Since his retirement, Medtronic does not have huge presence in the obesity but certainly has presence in the CV space.
Obesity is going to be the biggest market in the health care space according to Hank Plain from Morganthiler Ventures addressing the panel at OneMed Forum. He was talking for Satiety, Inc, rumors are the technology was acquired for$300 Million, which is 5x lower than the expected return for the VCs.
Today, after the reform of the FDA, Reshape Medical, Onciomed, Inc are at the forefront of the obesity technology. Both companies are located in OC, Ca
In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias.
Medtronic had acquired CoreValve for about $700 Million. CoreValve set the precedent that OUS clinical study is really valuable. CoreValve's technology was in the aortic valve market which is approx a $4 B market worldwide.
With the introduction of the CoreValve Evolut valve, Medtronic can now treat the broadest range of TAVI patient valve sizes (annulus diameters from 18mm to 29mm).
The Medtronic CoreValve System received CE (Conformite Europeenne) Mark in 2007. Medtronic now offers TAVI in four valve sizes (23mm, 26mm, 29mm and 31mm), each deliverable via transfemoral, subclavian and direct aortic access through a low-profile, 18Fr delivery catheter.
There are a few new start ups in the cardiac valves space, Micardia, spunoff a percutaneous approach and ORbimed invested in the company. Its wierd, Edwards is heavy in the space, market size is $4 B.
Medtronic's Ex CEO, Mr Bill Hawkins mentioned at the Cleveland Clinic Innovation Summit focused on Obesity. He mentioned that Medtronic's will be focusing on obesity and related problems. Since his retirement, Medtronic does not have huge presence in the obesity but certainly has presence in the CV space.Obesity is going to be the biggest market in the health care space according to Hank Plain from Morganthiler Ventures addressing the panel at OneMed Forum. He was talking for Satiety, Inc, rumors are the technology was acquired for$300 Million, which is 5x lower than the expected return for the VCs.
Today, after the reform of the FDA, Reshape Medical, Onciomed, Inc are at the forefront of the obesity technology. Both companies are located in OC, Ca
In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias.
No comments:
Post a Comment